---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-24-000089"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:20:33.691113+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Summit Therapeutics enters $90M ATM equity distribution agreement with JPMorgan

## Summary
- Up to $90M of common stock may be sold at-the-market through J.P. Morgan Securities LLC as sales agent.
- Company has no obligation to sell any shares; sales at prevailing market prices or negotiated prices.
- Sales agent commission is up to 3.0% of gross proceeds per share sold.
- Offerings made under existing S-3 shelf registration (File No. 333-277169) declared effective Feb 27, 2024.

## SEC filing metadata
- accession: 0001599298-24-000089
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000089/0001599298-24-000089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000089/smmt-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-24-000089
- JSON: https://secwatch.observer/filing/0001599298-24-000089.json
- Plain text: https://secwatch.observer/filing/0001599298-24-000089.txt

## Key facts
- Material Agreements
  Summit Therapeutics Inc. entered into Distribution Agreement with J.P. Morgan Securities LLC valued at up to $90,000,000 (effective 2024-05-13).
  - Action: entry
  - Agreement: atm program
  - Counterparty: J.P. Morgan Securities LLC
  - Value: up to $90,000,000
  - Effective: 2024-05-13
  source text: On May 13, 2024, Summit Therapeutics Inc. (the “Company”) entered into a distribution agreement (the “Distribution Agreement”) with J.P. Morgan Securities LLC (“Sales Agent”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares of the Company’s common stock, par value $0.01 per share, having an aggregate offering price of up to $90,000,000 (the “Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000089/0001599298-24-000089-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.